孟鲁司特联合沙丁胺醇对哮喘患儿血清TNF-α、IL-10、IL-13因子水平的影响

Effects of montelukast combined with salbutamol on the levels of serum TNF-α,IL-10 and IL-13 factors in children patients with asthma

目的分析孟鲁司特联合沙丁胺醇对哮喘患儿血清TNF-α、IL-10、IL-13因子水平的影响。方法选取2017年12月至2019年5月在我院接受治疗的哮喘患儿82例作为研究对象,按照随机数字表法分为两组,每组各41例,其中对照组接受沙丁胺醇治疗,观察组接受孟鲁司特联合沙丁胺醇治疗。比较两组患儿的治疗总有效率、日间症状积分、夜间症状积分、血清TNF-α、IL-10、IL-13因子水平、临床症状改善时间。结果观察组患儿的治疗总有效率为97.56%,高于对照组的80.49%,差异有统计学意义(P<0.05);治疗后观察组患儿的日间症状积分为(0.49±0.03)分、夜间症状积分为(0.74±0.06)分,低于对照组的(1.26±0.13)分、(1.68±0.15)分,差异有统计学意义(P<0.05);治疗后观察组患儿的血清TNF-α为(78.29±7.63)ng/L、IL-10为(22.15±2.08)ng/L、IL-13为(5.54±0.53)ng/L,低于对照组的(105.14±9.84)ng/L、(28.36±2.64)ng/L、(9.97±0.93)ng/L,差异有统计学意义(P<0.05);治疗后观察组患儿的气促缓解时间为(3.08±0.26)d、憋喘消失时间为(4.02±0.37)d、咳嗽消失时间为(4.43±0.40)d、肺啰音消失时间为(4.55±0.41)d、肺部哮鸣音消失时间为(4.35±0.41)d,低于对照组的(4.21±0.39)d、(5.36±0.51)d、(6.08±0.58)d、(5.49±0.52)d、(6.28±0.60)d,差异有统计学意义(P<0.05)。结论小儿哮喘患儿接受沙丁胺醇联合孟鲁司特治疗,可以有效降低炎症因子水平、促进患儿临床症状的改善、提高疾病治疗效果,值得推广应用。

Objective To analyze the effect of montelukast combined with salbutamol on the levels of serum TNF-α, IL-10 and IL-13 in children patients with asthma. Methods A total of 82 children patients with asthma who were treated in our hospital from December 2017 to May 2019 were selected as the study subjects. They were divided into two groups according to the random number table method, with 41 cases in each group. The control group was given salbutamol for treatment, and the observation group was given montelukast combined with salbutamol for treatment. The total treatment efficiency, the score of day symptoms, the score of night symptoms, the levels of serum TNF-α, IL-10, and IL-13 factors and the time to improve clinical symptoms were compared between the two groups of children patients. Results The total effective rate of treatment in the observation group was 97.56%, which was significantly higher than 80.49% in the control group, and the difference was statistically significant(P<0.05);after treatment, the score of day symptoms was (0.49±0.03) points and the score of night symptoms was (0.74±0.06) points in the observation group, lower than(1.26±0.13) points and (1.68±0.15) points of the control group, the differences were statistically significant(P<0.05);after treatment, TNF-α in the observation group was(78.29±7.63) ng/L, IL-10 was(22.15±2.08) ng/L, and IL-13 was(5.54±0.53) ng/L, lower than(105.14±9.84) ng/L,(28.36±2.64) ng/L and(9.97±0.93) ng/L of the control group, the differences were statistically significant(P<0.05);after treatment, the time for shortness of breath relief was(3.08±0.26) d, the breathlessness disappearing time was(4.02±0.37) d, the cough disappearing time was(4.43±0.40) d, the lung rales disappearing time was(4.55±0.41) d, and the lung wheeze disappearing time was(4.35±0.41) d in the observation group, lower than(4.21±0.39) d, (5.36±0.51) d, (6.08±0.58) d, (5.49±0.52) d, (6.28±0.60) d, of the control group, the differences were statistically significant(P<0.05). Conclusion Salbutamol combined with montelukast for children patients with asthma can effectively reduce the levels of inflammatory factors, promote the improvement of clinical symptoms, and improve the therapeutic effect of the disease, which is worthy of popularization and application.